3022 - STARBURST: Phase 2 Study of <sup>89</sup>Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of Carbonic Anhydrase IX (CAIX)

05:00pm - 06:00pm PT

Hall F

Screen: 3

Presenter(s)

David Cade, - Telix Pharmaceuticals, Fishers, IN